E-LIB Suche - Ergebnisse für: Reich, K

1

Abrocitinib effect on patient‐reported outcomes in patients..:

Reich, K. ; Silverberg, J. I. ; Papp, K. A....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 10 - p. 2047-2055 , 2023

Link: https://doi.org/10.1111/..

2

Patient and physician outcomes of a store‐and‐forward teled..:

Otten, M. ; Greis, C. ; Reinders, P....
Journal of the European Academy of Dermatology and Venereology. 38 (2023) 2 - p. , 2023

Link: https://doi.org/10.1111/..

3

Climatological changes and new applications for system grid..:

, In: 27th International Conference on Electricity Distribution (CIRED 2023),

Weindl, K. ; Schwalt, L. ; Reich, K. - p. None , 2023

Link: https://doi.org/10.1049/..

4

Higher levels of response on clinical atopic dermatitis sev..:

Reich, K. ; de Bruin‐Weller, M. S. ; Deleuran, M....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 8 - p. 1634-1641 , 2023

Link: https://doi.org/10.1111/..

5

Early disease intervention with guselkumab in psoriasis lea..:

Schäkel, K. ; Reich, K. ; Asadullah, K....
Journal of the European Academy of Dermatology and Venereology. 37 (2023) 10 - p. 2016-2027 , 2023

Link: https://doi.org/10.1111/..

6

Super‐response to guselkumab treatment in patients with mod..:

Reich, K. ; Gordon, K.B. ; Strober, B....
Journal of the European Academy of Dermatology and Venereology. 36 (2022) 12 - p. 2393-2400 , 2022

Link: https://doi.org/10.1111/..

7

Long‐term efficacy and safety of brodalumab in moderate‐to‐..:

Reich, K. ; Iversen, L. ; Puig, L....
Journal of the European Academy of Dermatology and Venereology. 36 (2022) 8 - p. 1275-1283 , 2022

Link: https://doi.org/10.1111/..

8

Network meta‐analyses in psoriasis: overview and critical d..:

Augustin, M. ; Valencia López, M. ; Reich, K.
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 12 - p. 2367-2376 , 2021

Link: https://doi.org/10.1111/..

9

EuroGuiDerm Guideline on the systemic treatment of Psoriasi..:

Nast, A. ; Smith, C. ; Spuls, P.I....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 2 - p. 281-317 , 2021

Link: https://doi.org/10.1111/..

10

PBI3 Comparative Efficacy of Bimekizumab for the Treatment ..:

Armstrong, A. ; Reich, K. ; Warren, R.B....
Value in Health. 24 (2021) - p. S14 , 2021

Link: https://doi.org/10.1016/..

11

Effect of baseline disease severity on achievement of treat..:

Reich, K. ; Mrowietz, U. ; Menter, A....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 12 - p. 2409-2414 , 2021

Link: https://doi.org/10.1111/..

12

Long‐term safety of risankizumab from 17 clinical trials in..:

Gordon, K.B. ; Lebwohl, M. ; Papp, K.A....
British Journal of Dermatology. 186 (2021) 3 - p. 466-475 , 2021

Link: https://doi.org/10.1111/..

13

Quality of psoriasis care in Germany – results from the nat..:

Langenbruch, A. ; Mohr, N. ; Kirsten, N....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 7 - p. 1536-1542 , 2021

Link: https://doi.org/10.1111/..

14

Association of sex and systemic therapy treatment outcomes ..:

Maul, J.‐T. ; Augustin, M. ; Sorbe, C....
British Journal of Dermatology. 185 (2021) 6 - p. 1160-1168 , 2021

Link: https://doi.org/10.1111/..

15

Efficacy of secukinumab and adalimumab in patients with pso..:

Gottlieb, A.B. ; Merola, J.F. ; Reich, K....
British Journal of Dermatology. 185 (2021) 6 - p. 1124-1134 , 2021

Link: https://doi.org/10.1111/..